BURLINGAME, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its lead programs, CPI-444 and CPI-006, at the European Society for Medical Oncology (ESMO) 2018 Congress, which is taking place October 19-23 in Munich, Germany, and the Society for Immunotherapy of Cancer (SITC) 33^rd Annual Meeting, which is taking place November 7-11 in Washington, D.C.

Corvus will present data on CPI-444 from its ongoing Phase 1/1b trial at ESMO in a poster session:

Title: Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444
Presenter: Stephen Willingham, Corvus Pharmaceuticals
Poster Discussion Session: Immuno 2
Presentation Date and Time: October 22, 2018 from 9:30 – 10:40 a.m. CEST

Corvus will present data on CPI-444 and CPI-006 from their ongoing Phase 1/1b trials at SITC in an oral presentation and in two poster sessions:

Title: Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444
Presenter: Lawrence Fong, M.D., University of California, San Francisco
Presentation Date and Time: Saturday, November 10, 2018 from 4:40-4:55 p.m. ET

Title: Preclinical and initial Phase I clinical characterization of CPI-006: an anti-CD73 monoclonal antibody with unique immunostimulatory activity
Presenter: Emily Piccione, Corvus Pharmaceuticals
Poster Number: P205
Poster Presentation Hours: Friday, November 9, 2018 from 12:45-2:15 p.m. and 6:30-8:00 p.m. ET
Poster Hall Location: Hall E of the Walter E. Washington Convention Center

Title: Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444
Presenter: Drew Hotson, Corvus Pharmaceuticals
Poster Number: P54
Poster Presentation Hours:  Saturday, November 10, 2018 from 12:20-1:50 p.m. and 7:00-8:30 p.m. ET
Poster Hall Location: Hall E of the Walter E. Washington Convention Center

About Corvus Pharmaceuticals  
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidate, CPI-444, a small molecule inhibitor of the A2A receptor, is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. In May 2017, Corvus and Genentech expanded the collaboration and are now conducting a trial of CPI-444 and atezolizumab in patients with non-small cell lung cancer (NSCLC) who have failed prior therapies with anti-PD-(L)1 and platinum based chemotherapy. Corvus is evaluating a second product candidate, CPI-006, a humanized monoclonal antibody directed against CD73, in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com 

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@w2ogroup.com

Source: Corvus Pharmaceuticals, Inc.